LONDON, April 30, 2014 /PRNewswire/ --
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average finished the day 0.53% higher at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The gains were board based as eight out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 671.98, up 0.62%, and the index has advanced 4.72% in the previous three months. Investor-Edge has initiated coverage on the following equities: Becton Dickinson and Co. (NYSE: BDX), Thoratec Corp. (NASDAQ: THOR), Haemonetics Corp. (NYSE: HAE) and Antares Pharma Inc. (NASDAQ: ATRS). Free technical research on BDX, THOR, HAE and ATRS can be downloaded upon signing up at:
Shares in Becton Dickinson and Co.'s finished the Tuesday's session 0.56% lower at $112.18. A total of 0.81 million shares were traded, which was below its three months average volume of 0.90 million shares. The stock moved between $112.07 and $113.58 during the session. Over the last three months and since the beginning of 2014, Becton Dickinson and Co.'s shares have advanced 4.12% and 1.53%, respectively. However, the stock has declined 2.91% in the last one month. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $114.88 is greater than its 200-day moving average of $107.38. Becton Dickinson and Co.'s stock traded at a PE ratio of 19.09 and has a Relative Strength Index (RSI) of 44.14. Sign up today to read free research on BDX at:
On Tuesday, shares in Thoratec Corp. traded between $32.32 and $32.90 before ending the session 1.05% higher at $32.70. Thoratec Corp.'s stock reported a trading volume of 0.33 million shares, much below to its three months average volume of 0.65 million shares. The company stock traded at a PE ratio of 24.39. Thoratec Corp.'s shares have declined 1.98% in the previous three trading sessions, 6.97% in the last one month, and 10.66% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $35.13 and $36.63, respectively. Additionally, shares of the company have an RSI of 34.85. Sign up today to read free research on THOR at:
Haemonetics Corp.'s stock declined 1.89%, to close the day at $30.60. The stock recorded a trading volume of 0.62 million shares, which is at par with its three months average volume. The stock oscillated between $30.60 and $31.19 during the session. Over the previous three trading sessions and over the last one month, Haemonetics Corp.'s shares have declined 8.77% and 4.70%, respectively. Additionally, from the beginning of 2014, the company's stock has plummeted 27.37%. The stock is trading below its 50-day and 200-day moving averages. The company stock's 200-day moving average of $39.65 is above its 50-day moving average of $34.99. Further, the stock traded at a PE ratio of 17.58 and has an RSI of 30.77. Sign up today to read free research on HAE at:
On Tuesday, shares in Antares Pharma Inc. recorded a trading volume of 1.37 million shares, lower than its three months average volume of 1.61 million shares. The stock finished the day at 5.05% higher at $2.91, and registered an intraday range of $2.78 and $2.94. Antares Pharma Inc.'s shares have declined 0.34% in the previous three trading sessions, 18.03% in the last one month and 34.91% on YTD basis. Furthermore, the company's stock is trading below its 50-day and 200-day moving averages of $3.83 and $4.18, respectively. Shares of the company have an RSI of 26.32. Sign up today to read free research on ATRS at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.